Telix Pharmaceuticals' Quarterly Revenue Exceeds AU$200M Mark

2 min read | October 18, 2024 11:42 AM AEDT | By Team Kalkine Media

Google News:

Telix Pharmaceuticals' Quarterly Revenue Exceeds AU$200M Mark — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Telix Pharmaceuticals reports AU$201M in quarterly revenue.

Sales growth driven by prostate cancer imaging product, Illuccix.

Company expects full-year revenue to reach between AU$745M to AU$776M.

Telix Pharmaceuticals (ASX:TLX) has reported impressive quarterly revenue figures, surpassing AU$200 million. The company has also reaffirmed its full-year 2024 revenue guidance, demonstrating its strong performance in the radiopharmaceutical sector.

For the recent quarter, Telix Pharmaceuticals achieved AU$201 million in revenue, a significant portion of which came from sales of its prostate cancer imaging product, Illuccix. This product is part of the company's precision medicine business unit, and it has been central to driving growth in both sales and market share. Notably, this quarterly revenue marks a 55% increase from Q3 2023, when revenue totaled AU$133 million. It also reflects a 9% rise from Q2 2024, where revenue was AU$189 million.

Telix Pharmaceuticals continues to strengthen its position in the U.S. market, leveraging its sales and marketing strategies to expand adoption and reinforce its leadership in the urology market with its PSMA3 imaging technology. The company's focus on expanding its market share for Illuccix has been key to its revenue growth.

In a notable move to expand its North American manufacturing capabilities, Telix Pharmaceuticals acquired RLS (USA) Inc for a reported US$230 million. This acquisition will further enhance the company's ability to meet the growing demand for its products in the region.

Telix Pharmaceuticals’ CEO, Christian Behrenbruch, expressed pride in the company's accomplishments, stating that the past quarter's performance highlights Telix’s leadership in the radiopharmaceutical field. He also noted the company’s progress in advancing multiple late-stage therapeutic assets and preparing for the commercialization of three new imaging agents within its precision medicine portfolio.

In addition to its financial performance, Telix Pharmaceuticals underwent a business reorganization during the third quarter, aligning its operations across four distinct business units. The new structure consists of Therapeutics, Precision Medicine (Diagnostics), Lightpoint (MedTech), and Telix Manufacturing Solutions (TMS). This reorganization reflects the company's focus on becoming a therapeutics-led radiopharmaceutical organization.

Looking ahead, Telix Pharmaceuticals has provided guidance for its full-year 2024 revenue, expecting it to fall between AU$745 million and AU$776 million. This represents an estimated 48% to 54% increase compared to the full year 2023, underscoring the company's ongoing momentum.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.